ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CLEC4C

CLEC4C

概要

Name:C-Type lectin domain family 4 member C
Target Synonym:DLEC,HECL,C-type lectin superfamily member 7,CLEC4C,BDCA2,UNQ9361/PRO34150,C-type lectin domain family 4 member C,Dendritic lectin,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7,C-Type Lectin Domain Family 4, Member C,CLECSF11,CLECSF7,BDCA-2,C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 11,Blood Dendritic Cell Antigen 2 Protein,Blood Dendritic Cell Antigen 2,Dendritic Cell Lectin B,CD303 Antigen,PRO34150,CD303
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
CLC-H5245 Human Human CLEC4C / BDCA2 Protein, His Tag
CLC-H5245-structure
CLC-H5245-sds
CLC-C52H4 Cynomolgus Cynomolgus CLEC4C / BDCA2 Protein, His Tag (MALS verified)
CLC-C52H4-structure
CLC-C52H4-sds
CLC-H5254 Human Human CLEC4C / BDCA2 Protein, Fc Tag
CLC-H5254-structure
CLC-H5254-sds
ACRO Quality

生物活性データの一部

CLC-C52H4-ELISA
 CLEC4C ELISA

Immobilized Cynomolgus CLEC4C, His Tag (Cat. No. CLC-C52H4) at 1 μg/mL (100 μL/well) can bind Litifilimab with a linear range of 0.06-2 ng/mL (QC tested).

CLC-C52H4-MALS-HPLC
CLEC4C MALS images

The purity of Cynomolgus CLEC4C, His Tag (Cat. No. CLC-C52H4) is more than 90% and the molecular weight of this protein is around 59-80 kDa verified by SEC-MALS.

Synonym Name

DLEC,CLEC4C,BDCA-2,CD303,CLECSF11,CLECSF7, HECL

Background

CLEC4C (C-type lectin domain family 4 member C), also known as BDCA2, CLECSF11, CLECSF7, DLEC and CD303. Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cell. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Litifilimab BIIB-059 Phase 3 Clinical Biogen Inc Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic Details
Litifilimab BIIB-059 Phase 3 Clinical Biogen Inc Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.

totopphone